Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
Clinical trial NCT03903562 · COMPLETED
Trial details
- NCT number
- NCT03903562
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-04-27
- Primary completion
- 2025-02-28
- Enrollment
- 1990
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.